Re-Entering Antibacterial Drug Development Summit



Antimicrobial resistance is recognized as one of the greatest threats in modern healthcare. Drug-resistant infections take a staggering toll in the United States and worldwide. The reasons for this situation are a dry new antibiotic pipeline, misuse and overuse of existing antibiotics, and the ingenuity of microbes that manage to develop resistance to literally every and any new antibacterial agent. One of the key elements for improving antimicrobial stewardship and drug development is rapid and accurate identification of the pathogens, as well as rapid and accurate antimicrobial susceptibility testing. CHI's inaugural Diagnostics to Guide Antimicrobial Stewardship and Drug Development conference, part of the Re-Entering Antibacterial Drug Development Summit, will provide a comprehensive overview of next generation tests and approaches to enhance stewardship of existing antibiotics, to diagnose and monitor resistance, and to enable clinical development of pathogen specific antibacterials.

2015 Conference at a Glance 

Antibacterial Research and Development

Novel Monoclonal Antibodies for the Prevention and Treatment of Bacterial Infections.

Steven J. Projan. Ph.D., Senior Vice President, R&D, Innovative Medicines unit, Head of Infectious Diseases & Vaccines, Medimmune

New Antibiotics from Natural Products

Kim Lewis, Ph.D., University Distinguished Professor, Director, Antimicrobial Discovery Center, Department of Biology, Northeastern University

Antibiotic Adjuvants To Reclaim Legacy Drugs

Gerard D. Wright, Ph.D., Director, Michael DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Canada Research Chair in Molecular Studies of Antibiotics

Bringing The Full Power Of Chemical Synthesis To Bear On The Discovery Of New Antibiotics

Andrew G. Myers. Ph.D., Amory Houghton Professor of Chemistry, Department of Chemistry & Chemical Biology, Harvard University

Gram-Negative Antibiotics: The Importance Of Compound Properties For Drug Discovery

Heinz E. Moser, Ph.D., Executive Director – Chemistry Infectious Diseases, Global Discovery Chemistry, Novartis Institutes for BioMedical Research


View Full Agenda 


Clinical Development and Commercialization of Antibacterials

Overcoming The Challenges Of Developing New Antibiotics For Resistant Bacteria With Regulatory Support And New Diagnostics

Barry Eisenstein, M.D., Senior Vice President, Scientific Affairs, Merck

New Business Models For Antibiotics: A Summary Of Recent Initiatives And Possible Future Directions

John Rex, M.D., Vice President and Head, Infection, Global Medicines Development, AstraZeneca


View Full Agenda 


Diagnostics to Guide Antimicrobial Stewardship and Drug Development

Latest Advances in Pathogen Detection

Kimberly E. Hanson, M.D., Medical Director, Mycology, Mycobacteriology, and Virology Laboratories, Section Chief, Microbiology, ARUP Laboratories

The Role Of The Microbiology Laboratory In Antimicrobial Stewardship Programs

Joint Presentation:
Karen C. Carroll, M.D., Director, Division of Microbiology, Department of Pathology, The John Hopkins Hospital
Edina Avdic, Pharm.D., MBA, Clinical Specialist, Infectious Diseases, Associate Director, Antimicrobial Stewardship Program, The John Hopkins Hospital


View Full Agenda 




For more details on the conference, please contact:
Marina Filshtinsky, M.D.
Senior Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5496
Email: mfilshtinsky@healthtech.com 


For exhibit & sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-972-5412, Fax: (781) 972-5470
email: cbenton@healthtech.com  



By Series:
By Region:


Conference
& Course Catalog

CHI Catalog 


Short Course DVDs